Patent ID: 8609614

Claim:
A method of attenuating a pathoangiogenic condition in a mammal, comprising administering to the mammal a composition comprising a polypeptide in an amount effective to induce or maintain an immune response to the Group B β-hemolitic streptococci (GBS) toxin receptor in the mammal, the immune response attenuating the pathoangiogenic condition, wherein the polypeptide comprises a mammalian GBS toxin receptor or is an immunogenic fragment of the GBS toxin receptor, wherein the GBS toxin receptor is capable of binding to GBS toxin CM101, wherein the pathoangiogenic condition is tumor growth, wherein the polypeptide is encoded by a nucleic acid sequence having greater than 95% sequence identity to SEQ ID NO:1, and wherein the fragment of the mammalian GBS toxin receptor has at least nine amino acids.